2017

1. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

   Journal of Hematology and Oncology, Vol. 10, Núm. 1

2. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

   Haematologica, Vol. 102, Núm. 1, pp. 168-175